Quinolones

07/01/1989 - "Thus, quinolones will continue to be most useful in the treatment of infections due to problem pathogens or to multiresistant pathogens (e.g., Pseudomonas species). "
01/01/1989 - "hominis was 1 microgram/ml, whereas the MIC50 for ureaplasmas was 8 micrograms/ml. Since the MIC50s for the most active quinolones approximate achievable concentrations in blood and urine, quinolones have promise in treating mycoplasmal infections."
11/01/2007 - "Among trials comparing quinolones to placebo or no treatment, a significant reduction in non-infection-related mortality was observed (relative risk 0.54, 95% confidence interval 0.32-0.93, 15 trials, 3,320 patients). "
10/01/2000 - "As previous studies suggest, the new quinolones have good activity against both aerobic and anaerobic bacteria so they are useful in the treatment of mixed infections (common feature of anaerobic infections)."
07/03/2001 - "bronchiseptica infections, and the strong PAE caused by quinolones may contribute to the in vivo efficacy of these drugs."

12/01/1989 - "Quinolones appear to have a limited role in the treatment of community-acquired pneumonia, since other established antibiotic regimens have been proven effective in such situations. "
02/15/2005 - "Although quinolones are often used to treat nosocomial pneumonia (NP), there have been few trials documenting their efficacy in treating NP. "
09/01/2008 - "Exposure-response analyses were performed using data from 89 patients (10 clinical trials) with Streptococcus pneumoniae community-acquired pneumonia who received quinolones. "
01/01/2013 - "To investigate the resistant mechanism of quinolones on multi-drug resistant Klebsiella caused pneumonia (MDR-KPN). "
04/01/2011 - "Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia."

12/01/2011 - "There was a substantial increase and change in the pattern of quinolone use between 1997 and 2009, a period during which quinolones that are effective for the treatment of respiratory tract infections were introduced. "
08/01/2006 - "There has been a substantial change in the use pattern of quinolones between 1997 and 2003, since the introduction of quinolones that are effective for the treatment of respiratory tract infections. "
04/01/2000 - "Quinolones are currently used as empirical therapy for treatment of community-acquired lower respiratory infections as they are effective against a broad range of conventional bacterial and 'atypical' pathogens, including Chlamydia pneumoniae. "
12/01/2000 - "Maxifloxacin and the new respiratory quinolones can be useful in the treatment of respiratory infections."
11/28/1994 - "Quinolones may be useful in the treatment of verified Gram-negative respiratory tract infections, but should always be preceded by susceptibility testing."

07/01/1994 - "Postcoital oral prophylaxis with minimal quinolone doses is highly effective in the prevention of recurrent urinary tract infections in women, because it achieves high urinary bactericidal concentrations, and clears the majority of the introital and urethral Enterobacteriaceae without inducing resistance to the quinolones despite long-term treatment. "
12/01/1992 - "In comparative clinical studies the quinolones have been shown to be effective in a short-course (3-5 days) or a single dose therapy in uncomplicated urinary tract infections. "
02/21/1986 - "The efficacy of quinolones in urinary tract infections has been shown in many studies. "
04/01/1991 - "Clinical trials of short-term (single dose vs three days) therapy with the newer quinolones conducted in women with uncomplicated lower urinary tract infections were reviewed. "
07/01/2015 - "Quinolones are one of the most frequently prescribed antimicrobials for the treatment of urinary tract infections. "

01/01/2008 - "Taken into consideration the cost raised of quinolones and cephalosporines, and in reference to the high mortality and frequent complications known of Hib meningitis, the introduction of immunization against Haemophilus influenzae in the Expanded Program Immunization should contribute to a better control of this disease."
11/01/1996 - "New quinolones should be considered as a therapeutic option for such mycobacterial meningitis."
01/01/2001 - "The newer quinolones may hold great promise for the treatment of serious bacterial infections, including meningitis, which are associated with prolonged FUO in developing countries."
12/01/2008 - "Risks of meningitis in case of digestive salmonellosis in infants urge discussion for preventive use of quinolones, particularly before the age of 6 months."
11/01/1998 - "With the exception of quinolones, many antibiotics appear to have prolonged sub-MIC effects and longer half-lives in CSF than in serum, suggesting that dosing intervals longer than those used traditionally would be effective in meningitis. "